# NextCure, Inc.: overview NXTC · Nasdaq · CIK 1661059 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nxtc.md) · [Financials](/companies/nxtc/financials.md) · [Filings](/companies/nxtc/filings.md) · [Insiders](/companies/nxtc/insiders.md) Latest reported revenue: [$0](/filings/0001558370-22-002824.md) for Q4 FY2020, three months to 2020-12-31, from the 10-K filed Mar 3, 2022 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001558370-22-002824). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(4.95)](/filings/0001104659-25-107036.md) | not reported | [(4.70)](/filings/0001104659-26-057187.md) | [(11.29)](/filings/0001104659-26-092050.md) | [(3.22)](/filings/0001104659-25-107036.md) | not reported | [(1.87)](/filings/0001104659-26-057187.md) | [(2.80)](/filings/0001104659-26-092050.md) | | Free cash flow | $m | [(11.6) d](/filings/0001104659-25-107036.md) | [(7.0) d](/filings/0001104659-26-024137.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.51)](/filings/0001558370-23-002698.md) | [(2.69)](/filings/0001558370-24-003672.md) | [(2.25)](/filings/0001558370-25-002402.md) | [(23.88)](/filings/0001104659-26-024137.md) | [(19.65)](/filings/0001104659-26-024137.md) | | Free cash flow | $m | [(59.6)](/filings/0001558370-23-002698.md) | [(56.0)](/filings/0001558370-24-003672.md) | [(53.8)](/filings/0001558370-25-002402.md) | [(41.3)](/filings/0001104659-26-024137.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nxtc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $461.3k | 288,303 | | Added +50,000 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $443.5k | 277,202 | | New +277,202 | | [Sofinnova Investments, Inc.](/funds/1631134.md) | 2026-06-30 | $356.2k | 222,654 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $273.9k | 171,202 | | Added +110,668 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $250.9k | 156,842 | | Reduced −3,631 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $141.0k | 88,112 | | New +88,112 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $135.5k | 84,687 | | Added +15,070 | | [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $103.1k | 64,464 | | Reduced −200,536 | | [Verdad Advisers, LP](/funds/1812822.md) | 2026-06-30 | $96.7k | 60,451 | | Added +17,496 | | [Pfizer Inc](/funds/78003.md) | 2026-06-30 | $73.0k | 44,347 | | Reduced −109,007 | ## Recent filings [All 385 filings](/companies/nxtc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-25 | 16:10 ET | [8-K](/filings/0001104659-26-110971.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-110971 | | 2026-09-03 | 16:10 ET | [8-K](/filings/0001104659-26-105057.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-105057 | | 2026-08-06 | 16:25 ET | [10-Q](/filings/0001104659-26-092050.md) | Quarterly report, period 2026-06-30 | 0001104659-26-092050 | | 2026-08-06 | 16:16 ET | [8-K](/filings/0001104659-26-092025.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-092025 | | 2026-07-14 | 07:00 ET | [8-K](/filings/0001104659-26-083326.md) | 1.01 Entry into a material agreement; 2.05 Exit or disposal costs; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-083326 | | 2026-06-25 | 08:01 ET | [8-K](/filings/0001104659-26-077546.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-077546 | | 2026-06-01 | 08:10 ET | [8-K](/filings/0001104659-26-068604.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-068604 | | 2026-05-07 | 16:25 ET | [10-Q](/filings/0001104659-26-057187.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057187 | | 2026-05-07 | 16:19 ET | [8-K](/filings/0001104659-26-057171.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-057171 | | 2026-04-24 | 16:15 ET | [DEF 14A](/filings/0001104659-26-048591.md) | Proxy statement, period 2026-06-18 | 0001104659-26-048591 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-024137.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1661059 - Tickers: NXTC - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 19:37 ET. No prices; not investment advice.